Pharma

Manufacturing Strategy Key to AGTC’s Next Steps for Gene Therapy Programs

By Rich Kirkner | August 18, 2020

As Applied Genetic Technologies Corp. takes the next steps in the development of its lead gene therapy candidate for inherited retinal disease, the company has…

Read More

Osmotica Will Commercialize and Supply Non-Surgical Droopy Lid Treatment via a Wholly Owned Subsidiary

By Conni Bergmann Koury | August 5, 2020

Last month, the US Food and Drug Administration approved a novel ophthalmic solution to treat acquired blepharoptosis, otherwise known as “droopy lid syndrome.” The solution,…

Read More
AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

By Steve Lenier | July 9, 2020

Weeks after completing its acquisition of Allergan, AbbVie is seeking a meeting with the US Food and Drug Administration to talk about the next steps…

Read More
With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

By Conni Bergmann Koury | July 1, 2020

Oyster Point Pharma has taken two big steps recently to advance development of its OC-01 nasal-spray candidate to treat dry eye disease: the closing of…

Read More
With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

By Steve Lenier | April 29, 2020

Developing a delivery system to replace eye drops has been an important unmet need in ophthalmology. Drops are difficult or impossible for some patients to…

Read More
Adverum, Gene Therapy, and AMD

Adverum, Gene Therapy, and AMD

By Steve Lenier | March 25, 2020

Adverum, a company pioneering novel gene therapies for ocular diseases, believes a gene therapy treatment for wet age-related macular degeneration (AMD) can reduce treatment burden…

Read More
CRISPR and inherited retinal disease

CRISPR and inherited retinal disease

By Keith Croes | March 18, 2020

Once again the eye proved to be the pioneer target in a new gene therapy approach, with the use in February of an agent utilizing…

Read More
2020’s Potential Retina Milestones

2020’s Potential Retina Milestones

By Rich Kirkner | February 26, 2020

As reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to…

Read More
Glaucoma 360: Promising data as the industry considers value

Glaucoma 360: Promising data as the industry considers value

By Heather Johnson | February 12, 2020

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF)…

Read More
Ranibizumab More Cost-Effective Than PRP

Ranibizumab More Cost-Effective Than PRP

By Vanessa Caceres | February 5, 2020

The use of ranibizumab 0.5 mg for proliferative diabetic retinopathy (PDR) compared with panretinal photocoagulation (PRP) appeared to be more cost effective for patients with…

Read More
Soft CL slows myopia in children

Soft CL slows myopia in children

By Keith Croes | January 22, 2020

Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to…

Read More
Lucentis and Eylea patent expirations in the micro-crystal ball

Lucentis and Eylea patent expirations in the micro-crystal ball

By Keith Croes | January 14, 2020

Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.